Université Paris-Saclay at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Université Paris-Saclay brings 2 presentations to ESGCT 2026 in Hamburg. Its work focuses on getting AAV gene therapy into the brain in Duchenne muscular dystrophy models. One line treats newborn mice to maximise dystrophin restoration in the brain, and another compares AAV serotypes for brain-wide delivery.

OrganizationESGCT 2026 Attendance
Poster
Thu Oct 29
2:00pm–4:00pm
Neonatal CNS-Directed AAV Therapies Maximize Brain Dystrophin Restoration in the mdx52 Mouse Model of Duchenne Muscular Dystrophy
CNS & sensory
Poster
Thu Oct 29
2:00pm–4:00pm
Selection of Optimal AAV Serotypes for Brain-Wide Gene Delivery Following Intracerebroventricular Injection in mdx52 Mice.
CNS & sensory

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Université Paris-Saclay

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction